Hikma Pharmaceuticals (LSE:HIK) Accounts Payable & Accrued Expense : £315 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Accounts Payable & Accrued Expense?

Hikma Pharmaceuticals's quarterly accounts payable & accrued expense increased from Dec. 2022 (£310 Mil) to Jun. 2023 (£458 Mil) but then declined from Jun. 2023 (£458 Mil) to Dec. 2023 (£315 Mil).

Hikma Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (£249 Mil) to Dec. 2022 (£310 Mil) and increased from Dec. 2022 (£310 Mil) to Dec. 2023 (£315 Mil).

Hikma Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Hikma Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Accounts Payable & Accrued Expense Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

291.47

273.05

248.91

310.34

315.21

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															248.91	271.21	310.34	457.78	315.21

Hikma Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines